Smartlab Europe

Pfizer recalls oral contraceptives due to packaging error

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Leveraging Global Drug Databases to Accelerate Research and Development

Accessing comprehensive global drug databases streamlines the drug development process, allowing researchers to utilize existing clinical data and regulatory benchmarks to shorten innovation cycles.

Drug Device Combination Products Driving Delivery Precision

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.
- Advertisement -

Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 and 14 lots of Norgestrel and Ethinyl Estradiol tablets in the US due to possibility of inexact tablet counts or out of sequence tablets.

The products are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. The products are packaged in blister packs containing 21 tablets of active ingredients and seven tablets of inert ingredients.

As a result of the packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy. The cause was identified and corrected immediately, the company said. The tablets were manufactured and packaged by Pfizer, commercialized by Akrimax Rx Products and labeled under the Akrimax Pharmaceuticals brand.

Latest stories

Related stories

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Leveraging Global Drug Databases to Accelerate Research and Development

Accessing comprehensive global drug databases streamlines the drug development process, allowing researchers to utilize existing clinical data and regulatory benchmarks to shorten innovation cycles.

Drug Device Combination Products Driving Delivery Precision

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.

ACG Packaging Materials Joins WEF Global Lighthouse Network

ACG Packaging Materials has announced that its Shirwal manufacturing...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »